ArticleG3 (Bethesda, Md.)2017
Comparative Genomics of Two Sequential
Article in G3 (Bethesda, Md.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 60 citations in OpenAlex.
- Accelerated mutator phenotype in a clinicalEmerging microbes & infections · 2026Article
- Urosepsis by multidrug-resistantmBio · 2026Article
- Article
- Review
- Uncovering actionable trade-offs of antifungal resistance in a yeast pathogen.Molecular systems biology · 2026Article
- Phylogenomic analysis and genetic mechanisms of antifungal resistance in clinical isolates ofMicrobiology spectrum · 2026Article
- Antifungal resistance: Emerging mechanisms and implications (Review).Molecular medicine reports · 2025Review
- Humanized Candida and NanoBiT Assays Expedite Discovery of Bdf1 Bromodomain Inhibitors With Antifungal Potential.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Evolutionary dynamics in gut-colonizing Candida glabrata during caspofungin therapy: Emergence of clinically important mutations in sphingolipid biosynthesis.PLoS pathogens · 2024Article
- Article
- Genomic description of acquired fluconazole- and echinocandin-resistance in patients with serialJournal of clinical microbiology · 2024Article
- Yeast metagenomics: analytical challenges in the analysis of the eukaryotic microbiome.Microbiome research reports · 2024Review
- Candida glabrata: A powerhouse of resistance.PLoS pathogens · 2023Article
- Redefining pleiotropic drug resistance in a pathogenic yeast: Pdr1 functions as a sensor of cellular stresses inmSphere · 2023Article
- Using Bioluminescence to Image Candida glabrata Urinary Tract Infections in Mice.Methods in molecular biology (Clifton, N.J.) · 2023Article
- UsingVirulence · 2022Article
- Multiple genome analysis ofMicrobial cell (Graz, Austria) · 2022Article
- Chromosome-level assemblies from diverse clades reveal limited structural and gene content variation in the genome of Candida glabrata.BMC biology · 2022Article
- Disclosing azole resistance mechanisms in resistant Candida glabrata strains encoding wild-type or gain-of-function CgPDR1 alleles through comparative genomics and transcriptomics.G3 (Bethesda, Md.) · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.